Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Vitae Pharmaceuticals, Inc (VTAE) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/25/2016 8-K Quarterly results
09/14/2016 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger by and between Allergan Holdco US, Inc., Augusta Merger Sub, Inc. and Vitae Pharmaceuticals, Inc.",
"Allergan to Acquire Vitae Pharmaceuticals Adding Innovative Development Programs for Dermatologic Conditions"
08/03/2016 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Vitae Pharmaceuticals Reports Second Quarter 2016 Operating and Financial Results",
"Presentation Slides Accompanying August 3, 2016 Vitae Pharmaceuticals Inc. Webcast"
07/27/2016 8-K Form 8-K - Current report
06/30/2016 8-K Form 8-K - Current report
05/26/2016 8-K Submission of Matters to a Vote of Security Holders
05/10/2016 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Vitae Pharmaceuticals Reports First Quarter 2016 Operating and Financial Results"
03/24/2016 8-K Form 8-K - Current report
03/23/2016 8-K Form 8-K - Current report
03/16/2016 8-K Form 8-K - Current report
03/03/2016 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Vitae Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Operating and Financial Results"
12/17/2015 8-K Termination of a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Vitae Pharmaceuticals Reports Top-Line Results from Remaining Monotherapy Arm of Phase 2 Clinical Trial of BI187004 in Overweight Type 2 Diabetes Patients"
12/10/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "Vitae Pharmaceuticals Opens Phase 2a Proof-of-Concept Trial of VTP-38543 in Atopic Dermatitis Patients"
11/19/2015 8-K Investor presentation
Docs: "Presentation Slides"
11/18/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "Vitae Pharmaceuticals Announces Positive Top-Line Results from a Phase 1 Multiple Ascending Dose Trial of VTP-43742"
11/05/2015 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Vitae Pharmaceuticals Reports Third Quarter 2015 Operating and Financial Results"
09/30/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Vitae Pharmaceuticals Appoints Dr. Karen Bernstein to Board of Directors"
09/29/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "Vitae Pharmaceuticals Initiates Second Part of a Phase 1 Multiple Ascending Dose Study of VTP-43742 in Psoriatic Patients"
09/08/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "Vitae Pharmaceuticals Announces Positive Top-Line Results from Initial Phase 1study of First-in-Class RORgt Inhibitor VTP-43742 in Autoimmune Disorders"
08/10/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "Vitae Pharmaceuticals Announces Initiation of a Phase 1 Multiple Ascending Dose Study of VTP-43742 in Autoimmune Disorders"
08/04/2015 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Vitae Pharmaceuticals Reports Second Quarter 2015 Operating and Financial Results"
07/29/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Vitae Pharmaceuticals Appoints Dr. John M. Leonard to Board of Directors"
07/27/2015 8-K Termination of a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Vitae Pharmaceuticals and Boehringer Ingelheim to End Collaboration and License Agreement for BACE Inhibitors"
06/29/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "Vitae Pharmaceuticals Announces Top-Line Results from Metformin Arm of Ongoing Phase 2 Clinical Trial of BI187004/VTP-34072 in Overweight Type 2 Diabetics",
"Vitae Pharmaceuticals Announces Initiation of a Phase 1 Single Ascending Dose Study of VTP-43742 in Autoimmune Disorders"
05/29/2015 8-K Submission of Matters to a Vote of Security Holders
05/12/2015 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Vitae Pharmaceuticals Reports First Quarter 2015 Operating and Financial Results"
03/31/2015 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
Docs: "Vitae Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Operating and Financial Results"
03/20/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/26/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "BACE Inhibitor BI 1181181 Voluntarily put on Temporary Clinical Hold for Safety Evaluation"
01/28/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "Vitae Pharmaceuticals Announces Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Follow-on Public Offering of Common Stock"
01/15/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/23/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Vitae Pharmaceuticals Added to Russell 2000® and Russell 3000® Indexes"
11/12/2014 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Vitae Pharmaceuticals Reports Third Quarter 2014 Operating and Financial Results"
10/27/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Vitae Pharmaceuticals Announces Exercise of Underwriters' Option to Purchase Additional Shares of Initial Public Offering"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy